What exactly did BMO change on March 02, 2026 for Vertex?

On March 02, 2026 BMO Capital maintained an Outperform rating and raised the price target to $600 for Vertex. The firm cited continued strength in core therapies and margin expansion as reasons for the higher target.

How should I interpret the VRTX analyst rating for my portfolio?

An Outperform rating means analysts expect VRTX to beat sector returns. Use it to weigh conviction and position size, but combine the rating with your risk tolerance and upcoming catalysts before trading.

Does the new $600 price target mean a near-term buy signal?

A $600 price target is a 12-month analyst view, not a guaranteed near-term price. It reflects upside if Vertex hits earnings and clinical milestones but is not an automatic buy trigger.

Where can I track other VRTX analyst rating moves?

Track real-time analyst coverage and aggregated moves on major feeds such as Investing.com and our Meyka VRTX page for live updates and historical ratings.

Analyst Ratings

BMO Maintains Outperform on VRTX, Vertex Pharmaceuticals Incorporated Mar 2026

ByHuzaifa Zahoor March 3, 2026March 3, 2026

BMO Capital maintained an Outperform rating and raised the price target to $600 for Vertex Pharmaceuticals Incorporated on March 02, 2026. The VRTX analyst rating update kept confidence in Vertex’s pipeline and recurring revenue model. BMO flagged continued growth from key therapies and steady cash generation. Investors should note the March 02 note, the new $600 target, and the minor intraday stock move of -0.3% ($-1.45) on the report day.